Glaucoma is the leading avoidable cause of blindness, after cataracts, for which surgery is now commonplace. Unlike cataracts, however, glaucoma’s progression can be halted with inexpensive eye drops.  The critical issue is the need to screen approximately 3 million Americans with undiagnosed glaucoma.  Today, screening is limited to well-off patients in the US and other Western countries.  Nearly all glaucoma-caused blindness could be avoided with inexpensive eyedrops, had it been detected in time.

Our focus is to provide early detection measures for Glaucoma to communities that lack the necessary resources, both financial and logisitcal, to tackle this disease.  We have developed a proprietary technology which we believe will be able effectively address these concerns.